Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

Faye A Sharpley¹, Faouzi Djebbari¹, Samih Fourali¹, Jaimal Kothari^{1

2}, John A Lynes³, Susan McLain-Smith⁴, Karthik Ramasamy^{1

2}

Affiliations

¹ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² NIHR Oxford Biomedical Research Centre Blood Theme, Oxford, UK.
³ Celgene Ltd, Uxbridge, UK.
⁴ pH Associates Ltd, Marlow, UK.

Free article

Faye A Sharpley et al. Leuk Lymphoma. 2020 Mar.

Free article

. 2020 Mar;61(3):732-736.

doi: 10.1080/10428194.2019.1683737. Epub 2019 Nov 27.

Faye A Sharpley¹, Faouzi Djebbari¹, Samih Fourali¹, Jaimal Kothari^{1

2}, John A Lynes³, Susan McLain-Smith⁴, Karthik Ramasamy^{1

2}

¹ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² NIHR Oxford Biomedical Research Centre Blood Theme, Oxford, UK.
³ Celgene Ltd, Uxbridge, UK.
⁴ pH Associates Ltd, Marlow, UK.

No abstract available

Comment in

Non-transplant eligible multiple myeloma: deciphering optimal first line regimens.
Vaxman I, Gertz M. Vaxman I, et al. Leuk Lymphoma. 2020 Mar;61(3):504-506. doi: 10.1080/10428194.2020.1716223. Epub 2020 Jan 24. Leuk Lymphoma. 2020. PMID: 31975634 No abstract available.